Aclaris Therapeutics completes enrollment for Phase 2 atopic dermatitis trial
Aclaris Therapeutics (NASDAQ:ACRS) announced it has successfully completed patient enrollment for its Phase 2 clinical trial of bosakitug (ATI-045), an investigational treatment for patients suffering from moderate-to-severe atopic dermatitis.





-640x360.jpg&w=1200&q=75)
-640x360.jpg&w=1200&q=75)













